At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Nivolumab, and 3 other interventions for Clear Cell Renal Cell Carcinoma and 3 related conditions. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This phase I/II trial studies the side effects of sitravatinib and how well it works with nivolumab in treating patients with kidney cancer that has spread to other places in the body. Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sitravatinib and nivolumab may work better in treating patients with kidney cancer.
Study Details
Timeline
Interventions
Correlative studies
Given IV
Ancillary studies
Ancillary studies
Given PO